Lentivirus-mediated superoxide dismutase1 gene delivery protects against oxidative stress-induced liver injury in mice

Liver International

Volumn 27, Issue 10, 2007, Pages 1311-1322

  Venugopal, Senthil Kumar ^a   Wu, Jian ^a   Catana, Andreea M ^a   Eisenbud, Lauren ^a   He, Song Qing ^a   Duan, Yu You ^a   Follenzi, Antonia ^b   Zern, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Catalase; Gene therapy; Lentivirus; Liver injury; Oxidative stress; SOD1

Indexed keywords

CARBON TETRACHLORIDE; COPPER ZINC SUPEROXIDE DISMUTASE; HYPOXANTHINE; LENTIVIRUS VECTOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LYSATE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PORTAL VEIN; PROTEIN EXPRESSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ACUTE DISEASE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHRONIC DISEASE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LENTIVIRUS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; TRANSGENES;

EID: 36348934574     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01612.x     Document Type: Article

References (47)

1. Wu J, Danielsson A, Zern MA. Toxicity of hepatotoxins: New insights into mechanisms and therapy. Expert Opin Investig Drugs 1999; 8: 585-607.
2. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: Where are we? World J Gastroenterol 2006; 12: 509-15.
3. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-76.
4. Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003; 27: 277-84.
5. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, et al. GSH transport in mitochondria: Defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 273: G7-17.
6. Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003; 124: 778-90.
7. Greenwel P. Acetaldehyde-mediated collagen regulation in hepatic stellate cells. Alcohol Clin Exp Res 1999; 23: 930-3.
8. Zhan SS, Jiang JX, Wu J, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-43.
9. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-43.
10. Ferlitsch A, Pleiner J, Mittermayer F, et al. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit Care Med 2005; 33: 2028-33.
11. Harrison SA, Ward JA, Schenker S. The role of vitamin E and C therapy in NASH. Am J Gastroenterol 2004; 99: 1862.
12. Gebhardt R. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med 2002; 68: 289-96.
13. Wellington K, Jarvis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-89.
14. Macmillan-Crow LA, Cruthirds DL. Invited review: Manganese superoxide dismutase in disease. Free Radic Res 2001; 34: 325-36.
15. Marklund SL. Extracellular superoxide dismutase. Methods Enzymol 2002; 349: 74-80.
16. Wheeler MD, Kono H, Yin M, et al. Delivery of the Cu/Zn-superoxide dismutase gene with adenovirus reduces early alcohol-induced liver injury in rats. Gastroenterology 2001; 120: 1241-50.
17. Perez MJ, Cederbaum AI. Adenovirus-mediated expression of Cu/Zn- or Mn-superoxide dismutase protects against CYP2E1-dependent toxicity. Hepatology 2003; 38: 1146-58.
18. Wu J, Liu L, Yen RD, et al. Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 2004; 40: 195-204.
19. He SQ, Zhang YH, Venugopal SK, et al. Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice. Liver Transplant 2006; 12: 1869-79.
20. Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol 2002; 346: 454-65.
21. Follenzi A, Sabatino G, Lombardo A, et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-60.
22. VandenDriessche T, Thorrez L, Naldini L, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-22.
23. Pfeifer A, Kessler T, Yang M, et al. Transduction of liver cells by lentiviral vectors: Analysis in living animals by fluorescence imaging. Mol Ther 2001; 3: 319-22.
24. Oertel M, Rosencrantz R, Chen YQ, et al. Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors. Hepatology 2003; 37: 994-1005.
25. Nguyen TH, Oberholzer J, Birraux J, et al. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther 2002; 6: 199-209.
26. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-9.
27. Condiotti R, Curran MA, Nolan GP, et al. Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochem Biophys Res Commun 2004; 320: 998-1006.
28. Follenzi A, Naldini L. HIV-based vectors. Preparation and use. Methods Mol Med 2002; 69: 259-74.
29. Liu SL, Degli Esposti S, Yao T, et al. Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 1995; 22: 1474-81.
30. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic releaseof interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes 2005; 54: 85-91.
31. Shirahashi H, Wu J, Yamamoto N, et al. Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transplant 2004; 13: 197-211.
32. Glantzounis GK, Salacinski HJ, Yang W, et al. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: A review. Liver Transplant 2005; 11: 1031-47.
33. Lehmann TG, Wheeler MD, Froh M, et al. Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation 2003; 76: 28-37.
34. Wheeler MD, Katuna M, Smutney OM, et al. Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther 2001; 12: 2167-77.
35. Tuma DJ, Casey CA. Dangerous byproducts of alcohol breakdown - focus on adducts. Alcohol Res Health 2003; 27: 285-90.
36. Dai L, Claxson A, Marklund SL, et al. Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes. Gene Ther 2003; 10: 550-8.
37. Jooss K, Ertl HC, Wilson JM. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 1998; 72: 2945-54.
38. Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13: 1281-91.
39. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
40. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
41. Thorrez L, VandenDriessche T, Collen D, Chuah MK. Preclinical gene therapy studies for hemophilia using adenoviral vectors. Semin Thromb Hemost 2004; 30: 173-83.
42. Nguyen TH, Ferry N. Liver gene therapy: Advances and hurdles. Gene Ther 2004; 11 (Suppl. 1): S76-84.
43. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-6.
44. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
45. Couto L, Parker A, Gordon JW. Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno-associated virus gene therapy vector fails to lead to germ cell transduction. Hum Gene Ther 2004; 15: 287-91.
46. Zamir G, Gelman AE, Olthoff KM, et al. Patterns of transgene expression and viral clearance from the transplanted liver following ex vivo adenovirus-mediated gene transfer. J Hepatol 2004; 41: 714-20.
47. Duan Y, Catana A, Gupta S, Zern MA. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells using a liver-specific lentivirus vector and laser microdissection. Hepatology 2006; 44: 204A.